Natus Medical (BABY) vs. The Competition Head-To-Head Comparison

Natus Medical (NASDAQ: BABY) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Natus Medical to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.

Institutional and Insider Ownership

94.6% of Natus Medical shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 5.5% of Natus Medical shares are held by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Natus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Natus Medical’s rivals have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Natus Medical and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natus Medical 1 1 1 0 2.00
Natus Medical Competitors 266 1840 3297 105 2.59

Natus Medical currently has a consensus price target of $48.00, indicating a potential upside of 15.52%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.97%. Given Natus Medical’s higher probable upside, research analysts plainly believe Natus Medical is more favorable than its rivals.

Profitability

This table compares Natus Medical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Natus Medical -0.62% 12.06% 7.53%
Natus Medical Competitors -327.98% -35.74% -12.50%

Earnings & Valuation

This table compares Natus Medical and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Natus Medical $445.49 million $48.00 million -461.62
Natus Medical Competitors $2.06 billion $438.96 million -77.91

Natus Medical’s rivals have higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Natus Medical beats its rivals on 7 of the 13 factors compared.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply